The authors are grateful to Ilona Garner, Department of Neurological Surgery, UCSF, for editing this manuscript. The findings and conclusions in this article have not been formally disseminated by the Food and Drug Administration and should not be construed to represent any Agency determination or policy.
The following institutions and investigators participated in the trial: City of Hope Medical Center, Duarte, California (Behnam Badie); Ohio State University Medical Center, Columbus, Ohio (Antonio Chiocca); H. Lee Moffitt Cancer Center, Tampa, Florida (Frank Vrinis); University of Hamburg-Eppendorf, Hamburg, Germany (M.W.); University of Schleswig–Holstein, Lubeck, Germany (Maximillian H. Mehdorn); Sheba Medical Center, Tel Hashomer, Israel (Zvi Cohen); Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Z.R.); The Cleveland Clinic Foundation, Cleveland, Ohio (G.B.); University of Colorado Hospital-Medical School, Aurora, Colorado (Kevin Lillehei); Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (Kevin Judy); Baylor College of Medicine, Houston, Texas (Pamela New); Emory University, Atlanta, Georgia (Jeffrey Olson); Henry Ford Health Systems, Detroit, Michigan (Tom Mikkelsen); University of Alabama at Birmingham, Birmingham, Alabama (James Markert); Wake Forest University Health Sciences, Winston-Salem, North Carolina (Stephen Tatter); John Hopkins Hospital, Baltimore, Maryland (Jon Weingart); The University of Texas M. D. Anderson Cancer Center, Houston, Texas (Fredrick Lang); Yale University School of Medicine, New Haven, Connecticut (J.P.); University of California–San Francisco, San Francisco, California (M.P.); Memorial Sloan Kettering Cancer Center, New York, New York (Lauren Abrey); Duke University Medical Center, Durham, North Carolina (David Reardon); Carolina Neurosurgery and Spine Associates, Charlotte, North Carolina (Anthony Asher); Dana Farber Cancer Institute, Boston, Massachusetts (Peter Black); Northwestern Medical Faculty Foundations, Inc., Chicago, Illinois (James Chandler); Evanston Northwestern Healthcare, Evanston, Illinois (Nina Paleologos); University of Wisconsin Hospital and Clinics, Madison, Wisconsin (John Kuo); Cedar Sinai Medical Center, Neurosurgical Institute, Los Angeles, California (John Yu); CINN at Rush University Medical Center, Chicago, Illinois (Richard Byrne); Medical University of South Carolina, Charleston, South Carolina (Sunil Patel); University of Virginia Health Systems, Charlottesville, Virginia (M.S.); Florida Hospital Neuroscience Institute, Orlando, Florida (Edward Pan); University of California–Los Angeles, Los Angeles, California (Timothy Cloughesy); Weill Cornell Medical College, Department of Neurological Surgery, New York, New York (Theodore Schwartz); University of Chicago Medical Center, Chicago, Illinois (Macieij Lesniak); Columbia University Medical Center, New York, New York (Jeffrey Bruce); University of Southern California, Los Angeles, California (Thomas Chen); Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada (Rolando Del Maestro); Cancer Care Manitoba, Winnipeg, Manitoba, Canada (David Eisenstat); Royal University Hospital, Saskatoon, Saskatchewan, Canada (Daryl Fourney); Toronto Western Hospital, Toronto, Ontario, Canada (Abhijit Guha); University of Utah, Salt Lake City, Utah (Randy L. Jensen); London Regional Cancer Program, London, Ontario, Canada (David MacDonald); Walter Mackenzie Health Sciences Center, Edmonton, Alberta, Canada (Vivek Mehta); University Hospital Groningen, Groningen, The Netherlands (Jan Jakob A. Mooij); Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada (Farhad Pirouzmand); Institute of Neurological Sciences, Southern General Hospital, Glasgow, United Kingdom (Laurence T. Dunn); Technische Universitat Dresden Klinic und Poliklinik fur Neuochirugie, Dresden, Germany (Gabriele Schackert); Ludwig-Maximilians-Universitat Munchen, Munich, Germany (Roland Goldbrunner); Mayo Clinic, Rochester, Minnesota (Joon Uhm); University of Heidelberg, Heidelberg, Germany (Andreas Unterberg); Erasmus University Medical Center, Rotterdam, The Netherlands (John G. Wolbers); Rabin Medical Center, Petah Tikva, Israel (Zvi Harry Rappaport); Calgary Health Region, Calgary, Alberta, Canada (Mark Hamilton); Baptist Memorial Hospital, Memphis, Tennessee (Bruce Frankel); West Virginia University, Robert C. Byrd Health Sciences Center, Morgantown, West Virginia (Warren Boling); St Louis University, St Louis, Missouri (Richard Bucholz); University of Texas Southwestern Medical Center, Dallas, Texas (Bruce Mickey); Oregon Health and Science University, Portland, Oregon (Johhny Delashaw Jr); Virginia Mason Clinic, Seattle, Washington (Lynne Taylor).
Conflict of interest statement. R.K.P. reports a Cooperative Research Development Agreement (CRADA) between the Food and Drug Administration and NeoPharm Inc., and he reports having a patent on the therapeutic agent described here, along with the NIH and Val-Chum. Rights are assigned to Secretary of the Department of Health and Human Services. M.V. reports serving as a consultant and receiving consulting fees for NeoPharm, Inc., Eisai, and Schering Plough and lecture fees from Schering Plough and Genentech.